OPK Share Price

Open 10.34 Change Price %
High 10.49 1 Day 0.09 0.87
Low 10.23 1 Week -0.43 -3.97
Close 10.40 1 Month 0.85 8.90
Volume 2901406 1 Year -0.65 -5.88
52 Week High 11.85
52 Week Low 7.12
OPK Important Levels
Resistance 2 10.64
Resistance 1 10.54
Pivot 10.37
Support 1 10.26
Support 2 10.16
NYSE USA Most Active Stocks
BAC 21.23 -1.26%
BAC 21.23 -1.26%
BAC 21.23 -1.26%
EMC 29.05 0.97%
EMC 29.05 0.97%
EMC 29.05 0.97%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
WSH 47.18 -2.86%
More..
NYSE USA Top Gainers Stocks
POM 26.93 26.79%
POM 26.93 26.79%
CAS 0.51 24.39%
CAS 0.51 24.39%
CAS 0.51 24.39%
CAS 0.51 24.39%
CAS 0.51 24.39%
VNR 0.91 19.74%
VNR 0.91 19.74%
P 13.33 16.11%
More..
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
OIBR 0.17 -43.33%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
More..

Opko Health Inc (NYSE: OPK)

OPK Technical Analysis 3
As on 2nd Dec 2016 OPK Share Price closed @ 10.40 and we RECOMMEND Buy for LONG-TERM with Stoploss of 9.79 & Buy for SHORT-TERM with Stoploss of 10.06 we also expect STOCK to react on Following IMPORTANT LEVELS.
OPK Target for December
1st Target up-side 11.52
2nd Target up-side 12.3
3rd Target up-side 13.08
1st Target down-side 9.28
2nd Target down-side 8.5
3rd Target down-side 7.72
OPK Other Details
Segment EQ
Market Capital 1259492736.00
Sector Healthcare
Industry Medical Appliances & Equipment
Offical website http://www.opko.com
OPK Address
OPK
4400 Biscayne Boulevard
Miami, FL 33137
United States
Phone: 305-575-4100
Interactive Technical Analysis Chart Opko Health Inc ( OPK NYSE USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Opko Health Inc
OPK Business Profile
Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. The company develops a range of solutions to diagnose, treat, and prevent various conditions, including point-of-care tests, laboratory developed tests, molecular diagnostics tests, and proprietary pharmaceuticals, and vaccines. Its product pipeline includes various pharmaceutical compounds and technologies in research and development for a range of indications and conditions. The company’s lead products comprise RayaldyTM, a vitamin D prohormone, which in phase III clinical development stage to treat secondary hyperparathyroidism in patients with stage III or IV chronic kidney disease and vitamin D insufficiency; and Alpharen, a new and potent non-absorbed phosphate binder to treat hyperphosphatemia in dialysis patients. It also manufactures, sells, and licenses specialty active pharmaceutical ingredients for pharmaceutical companies. In addition, the company is involved in the discovery of new drugs for the treatment of various illnesses, including cancer, heart disease, metabolic disorders, and genetic anomalies; and developing a protein-based influenza vaccine that would offer protection against influenza, as well as has various therapeutic agents for respiratory disorders in clinical development, including products for asthma, chronic obstructive pulmonary disease, and chronic cough. Further, it develops rolapitant, a potent and selective competitive antagonist that has completed phase II clinical testing for prevention of chemotherapy induced nausea and vomiting. It also operates OPKO Lab, a full-service medical laboratory specializing in urologic pathology. The company operates in the United States, Chile, Spain, Israel, Mexico, and Ireland. OPKO Health, Inc. is based in Miami, Florida.